Clarivate
`
`
`
`Webof Science”
`
`Search
`
`MarkedList
`
`History
`
`Alerts
`
`Search >
`
`Results >
`
`Results
`
` Engli
`
`Products
`
`
`
`
`
`483results from WebofScience CoreCollectionfor:
`Q "pulmonary hypertension" ANDtreprostinil(All Fields)
`| Citation Report AnalyzeResults
`co Copy query link
`Publications
`
`Youmayalso like...
`
`< Backtoall filters
`
`Refine by Publication Years
`
`Search for Publication Years
`
`OD select all
`
`DB 2022
`D 2021
`D 2020
`D 2019
`D 2018
`D 2017
`D 2016
`D 2015
`
`D 2014
`D 2013
`D 2012
`D 2011
`D 2010
`D 2009
`D 2008
`D 2007
`
`Date v
`
`26
`31
`16
`
`20
`15
`19
`13
`
`© 2006
`D 2005
`D 2004
`© 2003
`D 2002
`D 2001
`
`
`
`[eer
`Accelerating innovation
`
`ame
`TrainingPortal
`Product Support
`
`eRetcladiols)
`Privacy Statement
`Dg
`
`[efeyoar-iata)Celta}
`Cookie Policy
`Termsof Use
`
`Managecookie preferences
`
`
`
`Follow Us
`
`90
`
`Liquidia's Exhibit 1120
`Page 1
`
`Liquidia's Exhibit 1120
`Page 1
`
`

`

`
`
`
`
`
`
`deel acy
`
` a
`
`Signin v
`
`ate
`
`OCI
`
`Webof Science”
`
`Search
`
`MarkedList
`
`History
`
`Alerts
`
`Search >
`
`Results >
`
`Results
`
`
`
`55 results from WebofScienceCore Collection for:
`| Q “pulmonaryhypertension"ANDtreprostinil(AllFields)
` | reateAlert AnalyzeResults CitationReport
`Refined By: (Publication Years: 2001 or2002 or2003 or2004or2005 or2006 x) Clearall
`© Copyquery link
`Publications
`You mayalsolike...
`
`
`
`
`
`Refine results
`1
`of 2
`
`
`LD 0/55|Add To MarkedList Relevance v
`
`31
`O1
`Treatmentof HIV-associatedpulmonaryhypertension with treprostinil
`
`
`Citations
`QuickFilters
`Cea-Calvo,L; Subias,PE;(...); de la Calzada,CS
`
`Apr 2003 |REVISTAESPANOLADECARDIOLOGIA56(4) , pp.421-425
`OB Review Articles
`12
`13References
`
`
`Background andobjective. Thetreatmentofpulmonaryhypertension associated with infection by human immunodeficiency
`© B OpenAccess
`10
`virus has not been well defined. Treprostinil is a prostacyclin analogue that has recently been showntobe usefulfor the
`
`
`treatmentofpulmonaryhypertension, whetherprimary, secondary to congenitalheart disease,or as... Show more
`Related records
`FullText at Publisher
`°**
`
`Publication Years
`
`v
`
`10
`© 2006
`3Citations
`
`Transition from intravenous to subcutaneousprostacyclin inpulmonaryhypertension
`OD 2005
`15
`Subias,PE; Cea-Calvo,L; (...);delaCalzada,CS
`D 2004
`12
`Aug 2008 | REVISTA ESPANOLA DE CARDIOLOGIA 56(8) , pp.818-821
`© 2003
`ll
`eferences
`
`
`Treatmentofarterialpulmonaryhypertension with epoprostenol(intravenousprostacyclin) improvessurvival and quality of
`life, but the need for an implanted central venouscatheteris associated with frequent complications,that often (asin the case
`OD 2002
`6
`ofinfectionor dislodgment) are serious and require catheter replacement. Treprostinil is a prostacycl ...
`Showmore
`See all>
`FullText at Publisher FullText at Publisher
`°**
`
`Related records
`
`9R
`
`v
`Document Types
`155
`
`32
`CO Articles
`
` Efficacy of long-term subcutaneous treprostinil sodium therapyinpulmonaryhypertension
`
`
`Citations
`Lang,J;Gomez-Sanchez, M;(...); Vachiery,JL.
`
`CI ReviewArticles
`12
`Jun 2006 | CHEST129 (6) , pp.1636-1643
`CD MeetingAbstracts
`8
`25
`References
`Studyobjectives: Theaim of this long-term multicenter analysis wasto investigate whether subcutaneouslyinfused treprostinil
`C1 Editorial Materials
`2
`could provide sustained improvementsofexercise capacity and survival benefits in patients with pulmonary arterial
`O Letters
`1
`
`
`hypertension(PAH) andinoperable chronic thromboembolicpulmonaryhypertension (CTEPH). Subc ... Show more
`See all>
`Full
`T
`Publi
`eve
`
`v
`Webof Science Categories
`
`Sildenafil as a substitute for subcutaneousprostacyclin inpulmonaryhypertension
`
`
`oO Cardiac Cardiovascular Systems
`18
`itations
`Cea-Calvo,L; Subias,PE;(...); de la Calzada,CS
`OC Respiratory System
`15
`
`Oct 2008 |ARCHIVOSDEBRONCONEUMOLOGIA 39 (10) , pp.476-477
`9References
`oO Pharmacology Pharmacy
`12
`Subcutaneousprostacyclin (treprostinil) is an effective short-term treatmentforpulmonaryhypertension. The most frequently
`
`described adverse effect-pain in the areaofinjection-rarely requires that treatment be withdrawn.Sildenafil is a selective
`O Critical Care Medicine
`9
`fosfodiesterase-5 inhibitor with pulmonary vasodilating effects. We describetheuseofsildenafil as a ...Showmore
`O Medicine Generalinternal
`7
`Related records
`Full Text at Publisher
`°**
`See all>
`
`2C
`
`v
`Authors
`166Citations
`
`Efficacy andsafetyof treprostinil: An Epoprostenolanalogfor primarypulmonaryhypertension
`McLaughlin,VV; Gaine,SP;(...); Rich,S
`O Barst RJ
`7
`Feb 2003 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY41(2) , pp.293-299
`UO Seeger w
`7
`eferences
`Intravenous epoprostenolis currently FDA approved for managementof primarypulmonaryhypertension, butit requires
`
`OO EnkeB
`6
`intravenousinfusion andis associated with adverse effects. The objective ofthis study wasto evaluate the effects of an
`© olschewski H
`6
`
`
`epoprostenolanalog, treprostinil, for management ofpulmonaryhypertension. Tentertiary care acat ... Show more
`( ReichenbergerF
`6
`Related records
`Full Text at Publisher
`°*°
`See all>
`
`9R
`
`v
`Affiliations
`157
`
`Transition from intravenous epoprostenolto intravenous treprostinil inpulmonaryhypertension
`
`Citations
`Gomberg-Maitland,M; Tapson,VF; (...); Barst,RJ
`i] COLUMBIA UNIVERSITY
`8
`Dec 152005 | AMERICAN JOURNALOF RESPIRATORY AND CRITICAL CARE MEDICINE172(12) , pp.1586-1589
`oO UNITED THERAPEUTICS CORPORATION
`8
`Rationale: Intravenous epoprostenolimprovesexercise capacity and survivalin patients with pulmonaryarterial hypertension.
`(1 HOSPITAL UNIVERSITARIO 12 DEOCTUBRE
`6
`Theprostacyclin analog treprostinil is also efficacious by subcutaneousinfusion,is easier to administer, and hasa longerhalf-
`life. With the demonstrationof bioequivalence between subcutaneousandintravenoustreprostinil,ii ... Show more
`(7 UNIVERSITY OF MICHIGAN
`4
`Full
`Te
`Pi
`her
`°°°
`
`(J UNIVERSITY OF MICHIGAN SYSTEM
`4
`See all>
`
`R
`
`recor
`
`13
`References
`
`8C
`
`itations
`
`PublicationTitles
`
`v
`
`Treprostinil for the treatmentof severe digital necrosis in systemic sclerosis
`Engel,G and Rockson,SG
`2005 | VASCULAR MEDICINE10 (1) , pp.29-32
`5
`© cHest
`20References
`Wereport a caseof severedigital ulcerations associated with systemicsclerosis, successfully treated with treprostinil
`4
`(J) EUROPEAN HEART JOURNAL
`(Remodulin(R). There was improvementwithin daysofthe treatmentinitiation; complete healing was accomplishedafter 16
`oO AMERICAN JOURNALOF RESPIRATORYAND... 3
`weeksoftherapy.Patients with systemic sclerosis and peripheral small vessel disease havelimited th ... Showmore
`i] JOURNAL OF CARDIOVASCULAR PHARMAC...
`3
`Related records
`Free FullText From Publisher
`°**
`(J) EUROPEANRESPIRATORY JOURNAL
`2
`See all>
`
`Liquidia's Exhibit 1120
`Page 2
`
`Liquidia's Exhibit 1120
`Page 2
`
`

`

`11
`Os
`Publishers New
`Current and emergingtherapyfor primarypulmonaryhypertension
`
`
`Citations
`Pass,SE and Dusing, ML
`12
`
`Sep 2002 |ANNALSOFPHARMACOTHERAPY36(9) , pp.1414-1423
`OC Elsevier
`58References
`OBJECTIVE: To review the epidemiology, pathophysiology, clinical symptoms, and diagnostic workupof primary pulmonary
`© Lippincott Williams & Wilkins
`hypertension (PPH) andto discuss theavailable data onthecurrent and emerging therapies being used totreat this disorder.
`O wiley
`DATA SOURCES:Primary andreviewarticles were identified with a MEDLINE search (1966-December: ... Show more
`© AmerThoracic Soc
`Full Text at Publisher
`°°°
`O amerColl Chest Physicians
`See all>
`
`Related records
`
`weryn
`
`18
`D9
`Potent effects of aerosol comparedwith intravenous treprostinil on the pulmonarycirculation
`Citations
`Sandifer,BL; Brigham,KL; (...); Parker,RE
`Funding Agencies
`Dec 2005 | JOURNALOF APPLIED PHYSIOLOGY99 (6), pp.2363-2368
`31
`References
`
`
`Inhaled vasodilator therapy forpulmonaryhypertension maydecreasethe systemic side effects commonly observed with
`Open Access
`systemic administration. Inhaled medications only reach ventilated areasofthe lung,so local vasodilation may improve
`ventilation- perfusion matching and oxygenation. We comparedtheeffects of intravenousvs. aerosol... Show more
`.
`eee
`
`Editors
`
`Group Authors
`
`11
`Research Areas
`Treprostinil in advanced experimentalpulmonaryhypertension: Beneficial outcome without
`
`
`Citations
`reversed pulmonaryvascular remodeling
`van Albada, ME;van Veghel,R;(...); Berger, RFME
`31
`
`Nov 2006 |JOURNALOFCARDIOVASCULARPHARMACOLOGY48(5) , pp.249-254
`Countries/Regions
`References
`Introduction: Beneficialeffects of treprostmil, a stable prostacyclin analogue, were demonstratedin patients with pulmonary
`arterial hypertension (PAH). Although regression of pulmonary vascular remodeling has been suggested as therapeutic
`mechanism,its modeofaction remains unknown.
`... Show more
`Free Published Article From Repository Full Text at Publisher
`
`Languages
`
`ConferenceTitles
`
`Related records
`
`Favorable effects of inhaled - Treprostinil in severepulmonaryhypertension - Results from
`
`BookSeries Titles
`106
`O11
`
`
`Citations
`randomizedcontrolled pilot studies
`Webof Science Index
`Voswinckel,
`R; Enke,B; (...); Olschewski,H_
`
`Oct 17 2006 | JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY48 (8) , pp.1672-1681
`OBJECTIVESThis study soughtto investigate the effects of inhaled treprostinil on pulmonary hemodynamics and gas exchange
`
`
`in severepulmonaryhypertension.
`BACKGROUNDInhalediloprost therapy hasa provenclinicalefficacy in pulmonary arterial hypertens ... Show more
`Free
`FullText
`From
`Publisher
`***
`
`For moreoptions, use Analyze Results
`
`14
`References
`
`Continuous subcutaneousinfusion of treprostinil, a prostacyclin analogue, in patients with
`pulmonary arterial hypertension - A double-blind, randomized, placebo-controlledtrial
`
`Simonneau,G; Barst,RJ; (...); Rubin,LJ.
`CARE MEDICINE 165(6) , pp.800-804
`Mar 15 2002 | AMERI
`RNAL OF RESPIRATORY AND CRITICAL
`Pulmonaryarterial hypertensionisa life-threatening disease for which continuous intravenousprostacyclin has proven to be
`effective. However,this treatment requires a permanentcentral venouscatheterwith the associatedrisk ofserious
`complications suchassepsis, thromboembolism, or syncope. Treprostinil, a stable prostacyclin anak ...Showmore
`Related records
`Full Text at Publisher °°°
`
`968Citations
`
`26
`References
`
`0 12
`
`40Citations
`Pulmonaryhypertension in collagen vascular disease
`
`
`Mar2002 | EUROPEAN RESPIRATORY JOURNAL19 (3) , pp.571-576
`61
`References
`
`Pulmonaryhypertension is a serious but often overlooked complicationin collagen vascular disease. The understandingofthe
`
`
`developmentofpulmonaryhypertension hasincreased substantially duringthe last years.
`Abnormalproliferation of pulmonaryvascularcells is now being regarded as a predominantprocess ... Show more
`Free
`FullText
`From
`Publisher
`***
`
`33Citations
`McLaughlin,WV and Rich,S
`Oct 2004 |CURRENTPROBLEMSINCARDIOLOGY29(10) , pp.575-634
`
`
`142
`References
`
`Pulmonaryhypertension,in its simplest sense,is elevation ofthe pulmonary artery pressure above normal.A multitude of
`diseases may increase the pulmonaryartery pressure and resultin right ventricular dysfunction. The treatmentsof pulmonary
`hypertension areas varied asits causes. The past decadehasrealized remarkable growthin knowled ... Show more
`Free Submitted Article From Repository FullText at Publisher
`°**
`
`R
`
`recor
`
`opel
`
`70
`015
`
`
`Efficacy andsafety of sildenafil added to treprostinil inpulmonaryhypertension
`
`Citations
`Gomberg-Maitland,M; McLaughlin,V; (...); Rich,S
`Y 96 (9) , pp.1334-1336
`Nov 12005 | AMERICAN
`JOURNAL
`OF
`CARDIOL
`11
`Pulmonaryarterial hypertension (PAH)is characterized by abnormalities in endothelial and smooth musclecell function.
`References
`Prostacyclin released by endothelialcellsis a potent vasodilator by increasing cyclic adenosine monophosphate.Sildenafil, an
`inhibitor of phosphodiesterase-5, increases cyclic guanosine monophosphatein the lungs, produciny...Showmore
`Related records
`Full Text at Publisher °°°
`
`Comparisonandvalidation of three measuresofquality oflife in patients with pulmonary
`Chua, R; Keogh, AM;(...); O'Loughlin, A
`27
`Nov 2006|INTERNAL MEDICINEJOURNAL36 (11) , pp.705-710
`
`
`References
`
`
`Background:Pulmonaryhypertension, when advanced, markedly limits exercise capacity, activities of daily living and quality
`
`
`oflife (QoL). No measure ofQoLhasyetbeen validated forthe assessment ofpulmonaryhypertension. The aim ofthe study
`wasto comparethevalidity of the Minnesota Living with Heart Failure (MLwHF) questionnaire, the SF ... Showmore
`R
`recor
`Full
`Te
`Publisher °°
`
`47
`Citations
`
`
`
`Liquidia's Exhibit 1120
`Page 3
`
`Liquidia's Exhibit 1120
`Page 3
`
`

`

`Transitioning from IV epoprostenolto subcutaneous treprostinil in pulmonaryarterial
`hypertension
`
`Vachiery, JL; Hill,N; (...); Naeije,R
`
`May 2002 | CHEST121 (5) , pp.1561-1565
`Objective: ContinuousIV epoprostenol(prostacyclin) therapy improves survival and qualityoflife in patients with pulmonary
`arterial hypertension (PAH). IV epoprostenoltherapy maybelimited by serious complicationsrelated to the need for an
`implantedcentral venouscatheter, and its chemicalinstability and short half-life. Treprostinil isalon ... Showmore
`Related records
`Full Text at Publisher °°°
`
`78
`Citations
`
`16
`References
`
`Ov
`
`10
`D 18
`
`
`
`Treprostinil therapy forpulmonaryhypertensionartery
`Citations
`Horn,EMand Barst,RJ.
`Nov 2002 | EXPERT OPINION ON INVESTIGATIONAL DRUGS11 (11) , pp.1615-1622
`23
`References
`
`
`
`Pulmonaryhypertensionartery isa life-threatening disease characterised by a pulmonary vasculopathyandprogressive right
`ventricularfailure. Major advances were madewith the developmentofcontinuousintravenous epoprostenol(Flolan(TM)) as a
`treatment modality. Nevertheless,it is far from ideal as treatmentfor this disease. Subcutaneous trey «-Showmore
`Full Text at Publisher
`Related records
`
`Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute
`subcutaneousinfusion
`Wade, M; Baker, EJ; (...); Lai, AA
`12
`
`Jan 2004 |JOURNALOFCLINICALPHARMACOLOGY44 (1) , pp.83-88
`References
`Theobjectiveofthis study wasto evaluate the absolutebioavailability and acute pharmacokineticsoftreprostinil sodium
`administered by continuous, short-term subcutaneousinfusion in normalsubjects. Fifteen healthy volunteers received
`treprostinilvia anintravenousinfusion at 15 ng/kg/ min over150 minutes, followed by a 5- to 7-day v ... Show more
`Full Text at Publisher °°°
`
`019
`
`39
`Citations
`
`Related records
`
`0 20
`
`Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and
`pharmacokinetics of warfarin
`Wade, M; Hunt, TL and Lai, AA
`Jun 2003 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY41(6) , pp.908-915
`Treprostinil sodium wasrecently approvedin the United States for continuous subcutaneousinfusion in the treatmentof
`pulmonary arterial hypertension (PAH). Anticoagulation with warfarin is recommendedin PAH therapy. Giventhelikelihood for
`treprostinil and warfarin coadministration, a single-blind, controlled, crossover study was conducted ... Show more
`Full Text at Publisher
`°**
`
`16
`Citations
`
`22
`References
`
`Related records
`
`Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous
`subcutaneousinfusion
`Wade,M; Baker,FJ; (...);Lai,AA
`May 2004 |
`JOURNALOFCLINICAL PHARMACOLOGY44 (5) , pp.503-509
`Theobjective ofthis study wasto assess the pharmacokinetics and safety oftreprostinil sodium administered as a 28-day
`continuous subcutaneousinfusion at escalating infusionrates of 2.5 to 15 ng/kg/min in normal subjects. Fourteen healthy
`adult volunteers received a 28-day continuous subcutaneousinfusion oftreprostinil at escalatinginfi ...Showmore
`Related records
`Full Text at Publisher
`°°°*
`
`31Citations
`
`17
`References
`
`0 21
`
`15
`Citations
`
`8R
`
`Stability and preservative effectiveness of treprostinil sodium afterdilution in common
`intravenousdiluents
`Phares,KR; Weiser, WE;(...); Wade,M
`May12003 |AMERICANJOURNALOFHEALTH-SYSTEMPHARMACY60 (9) , pp.916-922
`
`
`
`
`eferences
`Thestability oftreprostinil sodiumafterdilutionin three commoniv.infusion vehicles was assessed.
`The chemicalstability oftreprostinil sodium wastested over a 48-hourperiod at 40 degreesC and 75% relative humidity after
`dilution in eachofthree diluents:sterile waterfor injection, 0.9% sodium chlorideinjection, and 5%¢... Show more
`Re
`recor
`Full
`Te
`Publisher °°
`
`D 22
`
`78
`Prostacyclin forpulmonaryhypertension in adults
`
`
`Citations
`Paramothayan,NS; Lasserson,TJ; (...); Walters,EH
`2005 | COCHRANE DATABASEOF SYSTEMATIC REVIEWS(2)
`98
`References
`
`
`Background Primarypulmonaryhypertension (PPH)is progressive,resulting in right ventricularfailure. Pulmonary
`hypertension can beidiopathicorassociated with other conditions. Prostacyclin is a potent vasodilatorand inhibitor of
`platelet aggregation, and canbegiven orally, subcutaneously, intravenously orinhaled via a nebulise ...Showmore
`Re
`recor
`Free Published Article From Repository FullText at Publisher
`°**
`
`DO 24
`
`Treprostinil (Remodulin (TM)) in connective tissue disease-associatedpulmonaryhypertension.
`Qudiz,RJ; Schilz,RJ;(...); Jeffs,RA
`Dec 2001 | ARTHRITIS AND RHEUMATISM44 (12), pp.2946-2946
`
`0R
`
`eferences
`
`0 25
`90Citations
`Prostacyclin andits analoguesin the treatmentofpulmonaryhypertension
`
`
`Olschewski,,H; Rose,F;(...); Seeger,W
`May 2004 | PHARMACOLOGY & THERAPEUTICS102 (2) , pp.139-153
`141
`Prostacyclin andits analogues (prostanoids)are potent vasodilators and possessantithrombotic andantiproliferative
`References
`properties.All of these properties help to antagonize the pathological changesthat take place in the
`Show more
`
`Liquidia's Exhibit 1120
`Page 4
`
`Liquidia's Exhibit 1120
`Page 4
`
`

`

`Full Text at Publisher °°°
`
`Transition from epoprostenol and
`in patients with
`Suleman, N and Frost, AE
`99th International Conferenceof the American-Thoracic-Society
`Sep 2004 | CHEST126 (3) , pp.808-815
`Study objectives: Priorto the availability of the oral endothelin antagonist bosentan, mostpatients with pulmonary arterial
`hypertension (PAH)weretreated with continuously infused prostacyclins. Many patients receiving prostacyclins would have
`received bosentanif it had been available at the timeof their diagnosis. Noninvasivecriteria (sympto ...Showmore
`Re
`recor
`Eull
`Te
`Publisher °°
`
`
`
`to the oral endothelin receptor antagonist bosentan
`
`37
`Citations
`
`13
`References
`
`24
`0 27
`Advancesin the treatment of secondarypulmonaryhypertension
`
`
`Citations
`Maloney,JP
`Mar 2003 | CURRENT OPINION IN PULMONARYMEDICINE9 (2) , pp.139-143
`17
`References
`
`Pulmonaryhypertension (PH)occurs frequently in parenchymallungdiseaseandis usually correlated with increased
`mortality, Thus,the treatmentof PHin patients with lungdisease has beenanactive areaofinterest. Secondary pulmonary
`hypertension (SPH), whetherfrom parenchymallung diseaseorotheretiologies, is more commonth... Showmore
`Related records
`Full Text at Publisher
`°°*
`
`8C
`
`Overviewoftreprostinil sodium for the treatmentof pulmonary arterial hypertension
`itations
`Budev, MM;Minai, OA andArroliga, AC
`
`Mar 2004 |DRUGSOFTODAY40(3) , pp.225-234
`45
`Pulmonaryarterial hypertensionis a life-threatening disorderthatrefers to a group of diseases characterized by an abnormal
`References
`elevation ofthe blood pressure within the pulmonarycirculation due to a vasculopathy ofthe pulmonary microcirculation(1).
`If left untreated, the overall prognosis of pulmonary arterial hypertensionis poor, with a 5-yearsurviy ... Show more
`Full
`Publi
`eve
`
`Role of prostacyclin versus peroxisomeproliferator-activated receptor beta receptorsin
`prostacyclin sensing by lung fibroblasts
`
`Ali,FY; Egan,(...); Mitchell,JA
`20
`Feb 2006 | AMERICAN JOURNALOF RESPIRATORY CELL AND MOLECULAR BIOLOGY34 (2) , pp.242-246
`References
`
`
`Prostacyclin and its mimetics are used therapeutically forthe treatment ofpulmonaryhypertension. These drugsactvia cell
`surface prostacyclin receptors(IP receptors); however, someof themcanalso activate the nuclear receptor peroxisome
`proliferator-activated receptor beta (PPARbeta). We examinedthepossibility that PPAR betais a ther... Show more
`Full Text at Publisher °°*
`
`70Citations
`
`Related records
`
`im :)
`
`0 30
`Inhaled treprostinil sodium (TRE) for the treatment ofpulmonaryhypertension
`
`
`Voswinckel,R; Enke,B;(...); Olschewski,H.
`77th Scientific Meeting of the American-Heart-Association
`Oct26 2004 | CIRCULATION 110(17) , pp.295-295
`
`0R
`
`eferences
`
`2C
`
`6R
`
`eferences
`
`D 31
`Combiningtreprostinil and sildenafil in the treatmentofpulmonaryhypertension
`
`
`itations
`Chua,Rand Keogh,A
`Nov 2005 | INTERNAL MEDICINE JOURNAL35 (11), pp.684-U3
`
`Eull
`
`Te
`
`Publisher °°
`
`R
`
`recor
`
`8C
`
`D 32
`Current medical treatment of pulmonaryarterial hypertension
`itations
`Sulica,R and Poon,M
`Mar 2004 | MOUNTSINAI JOURNALOF MEDICINE 71 (2), pp.103-114
`83
`References
`
`
`Primarypulmonaryhypertension is a rare disease of the pulmonaryvasculature manifested by dyspneaonexertion, syncope,
`
`andsigns and symptomsofrightheart failure. In the absenceof adequate treatment,primarypulmonaryhypertension has a
`grave prognosis, with a mediansurvivalof2.8 years. Pulmonary arterial hypertension developsin as: ... Showmore
`
`D 33
`Combination oforal sildenafil and inhaled treprostinil in severepulmonaryhypertension
`
`Voswinckel, R; Enke, B;(...); Olschewski, H
`27th Congressof the European-Society-of-Cardiology
`Sep 2005 | EUROPEAN HEART JOURNAL26, pp.113-114
`
`0R
`
`eferences
`
`1C
`
`0R
`
`eferences
`
`D 34
`
`Inhaled treprostinil is a potent pulmonaryvasodilatorin severepulmonaryhypertension
`itation
`
`Voswinckel,R; Kohstall,MG;(...); Olschewski,H
`ESC Congress 2004
`Aug-sep 2004 | EUROPEAN HEART JOURNAL25, pp.22-22
`
`Liquidia's Exhibit 1120
`Page 5
`
`Liquidia's Exhibit 1120
`Page 5
`
`

`

`37
`0 35
`Theprostacyclin analogue treprostinil blocks NF kappaBnucleartranslocation in human alveolar
`Citations
`a
`macrophages
`Raychaudhuri,B; Malur,A; (...); Inomassen,MJ
`32
`Sep 6 2002 | JOURNALOF BIOLOGICAL CHEMISTRY277 (36) , pp.33344-33348
`References
`
`
`Primarypulmonaryhypertension (PPH)is characterized by increased pulmonary arterial pressure and vascularresistance. We
`and others have observed thatinflammatory cytokines andinfiltrates are presentin the lungtissue, but the significanceis
`uncertain. Treprostinil (TRE), a prostacyclin analogue with extendedhalf-life and chemicalstability, h ...Showmore
`Free
`Full
`Text
`From
`Publi
`eee
`
`1C
`
`Role of prostacyclin andits derivatives in the treatment of pulmonaryarterial hypertension.
`itation
`Caneva,JO and Osses,JM
`2003 | MEDICINA-BUENOSAIRES63 (3) , pp.233-236
`16
`Role of prostacyclin andits derivatives in the treatmentof pulmonary arterial hypertension. Pulmonary arterial hypertension
`References
`(PAH)is defined as a groupofdiseases characterised by a progressive increase of pulmonary vascularresistance leading to
`right ventricularfailure and death. A dysregulation of prostacyclin metabolic pathways has been derr ... Show more
`ooo
`
`D 36
`
`R
`
`recor
`
`Liquidia's Exhibit 1120
`Page 6
`
`Liquidia's Exhibit 1120
`Page 6
`
`

`

`© Clarivate
`
`Web of Science’
`
`Search
`
`MarkedList
`
`History
`
`Alerts
`
`
`arated
`
`Signin
`
`
`Erta
`
`windIt at JH Libraries
`
`
`
`Add To MarkedList
`
`XS
`
`1
`
`of1
`
`>
`
`Inhaled treprostinil sodium (TRE) for the treatment of pulmonary hypertension
`By: Voswinckel, R (Voswinckel, R) ; Enke, B (Enke,B) ; Kreckel, A (Kreckel, A) ; Reichenberger, F (Reichenberger, F) ; Krick, S (Krick, S) ; Gall, H (Gall, H) ;
`Gessler, T (Gessler, T) ; Schmehl, T (Schmehl, T) ; Kohstall, MG (Kohstall, MG) ; Grimminger, F (Grimminger,F) ; ...More
`View WebofScience Researcher|D and ORCID (provided byClarivate)
`CIRCULATION
`Volume: 110 Issue: 17 Page: 295-295 Supplement: S Meeting Abstract: 1414
`Published: OCT 26 2004
`DocumentType: Meeting Abstract
`Conference
`Meeting: 77th Scientific Meeting of the American-Heart-Association
`Location: NewOrleans, LA
`Date: NOV 07-10, 2004
`Sponsor: AmerHeart Assoc
`Abstract
`
`AuthorInformation
`Addresses: Univ HospGiessen, Giessen, Germany
`Affiliation
`
`University Hospitalof Giessen & Marburg
`Categories/Classification
`Research Areas: Cardiovascular System & Cardiology
`
`+ See moredata fields
`
`.
`+
`Journal information
`CIRCULATION
`ISSN: 0009-7322
`eISSN: 1524-4539
`Current Publisher: LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCESQ,2001 MARKETST, PHILADELPHIA,PA 19103
`Research Areas: Cardiovascular System & Cardiology
`.
`.
`WebofScience Categories: Cardiac & Cardiovascular Systems;Peripheral Vascular Disease
`
`View category quartiles
`
`Citation Network
`In Webof Science CoreCollection
`0
`Citations
`& Createcitation alert
`
`Cited References
`
`0
`
`You mayalsolike...
`Hayes,D;Tobias, JD; Whitson,BA;et al.
`PULMONARYHYPERTENSIONIN CYSTIC
`FIBROSIS IN RELATION TO OTHER LUNG
`DISEASES PRIOR TO LUNG TRANSPLANTION
`PEDIATRIC PULMONOLOGY
`Cowburn, PJ; McArthur, JD; Cleland, JGF;etal.
`Pulmonary and systemic responsesto
`substanceP in patients with heartfailure with
`and without pulmonary hypertension
`JOURNAL OF THE AMERICAN COLLEGE OF
`CARDIOLOGY
`Bennett, J;
`Anaesthesia recommendationsfor
`Eisenmenger syndrome
`ANASTHESIOLOGIE & INTENSIVMEDIZIN
`Yuan, H; Wang,H;Peng,L;et al.
`REGULATION OFCIRCULATING MICRORNASIN
`OBSTRUCTIVE SLEEP APNEAPATIENTS WITH
`PULMONARY HYPERTENSION
`SLEEP
`Bray, JP; Adams, DR; Adams,PS;etal.
`Sugammadex Neuromuscular Blockade
`Reversal Associated With Lower Postoperative
`Arterial Carbon Dioxide Levels After Congenital
`Cardiac Surgery
`JOURNAL OF CARDIOTHORACIC AND
`VASCULAR ANESTHESIA
`See all
`
`Use in WebofScience
`WebofScience Usage Count
`
`0
`Last 180 Days
`Learn more
`
`4
`Since 2013
`
`This record is from:
`Webof ScienceCoreCollection
`© Science Citation Index Expanded(SCI-
`EXPANDED)
`© Conference Proceedings Citation Index -
`Science (CPCI-S)
`
`Suggest a correction
`
`Ifyou wouldlike to improve the quality ofthe
`datain this record, please Suggest a
`correction
`
`[pte
`Accelerating innovation
`
`(opsRen
`Bilameacle
`Product Support
`
`Data Correction
`Privacy Statement
`Naaciate
`
`(CyNinaelelay
`eelaoa]
`
`Bees
`
`Managecookie preferences
`
`io)OVO
`iy) rf)
`
`Liquidia's Exhibit 1120
`Page 7
`
`Liquidia's Exhibit 1120
`Page 7
`
`

`

`OCI
`
`
`
`Ely
`
`Web of Science”
`
`Search
`
`MarkedList
`
`History
`
`Alerts
`
`
`
`
`
`
`
`Products
`
`
`yc
`
`Signin v
`
`
`
`Add To MarkedList
`
`XS
`
`1
`
`ofi
`
`>
`
`Inhaled treprostinil is a potent pulmonary vasodilator in severe pulmonary hypertension
`By: Voswinckel, R (Voswinckel, R) ; Kohstall, MG (Kohstall, MG) ; Enke, B (Enke, B); Gessler, T (Gessler, T) ; Reichenberger, F (Reichenberger, F) ;
`Ghofrani, HA (Ghofrani, HA) ; Seeger, W (Seeger, W) ; Olschewski, H (Olschewski, H)
`View Webof Science Researcher|D and ORCID (provided byClarivate)
`EUROPEAN HEART JOURNAL
`Volume: 25 Page: 22-22 Supplement: S
`Published: AUG-SEP 2004
`DocumentType: Meeting Abstract
`Conference
`
`Meeting: ESC Congress 2004
`Location: Munich, GERMANY
`Date: AUG 28-SEP 01, 2004
`Sponsor: ESC
`AuthorInformation
`Addresses: Med Clin 2, DeptInternal Med, Giessen, Germany
`Categories/Classification
`Research Areas: Cardiovascular System & Cardiology
`
`+ See more datafields
`
`Journal information
`EUROPEAN HEART JOURNAL
`ISSN: 0195-668X
`Current Publisher: OXFORD UNIV PRESS, GREAT CLARENDONST, OXFORD OX2 6DP, ENGLAND
`Research Areas: Cardiovascular System & Cardiology
`WebofScience Categories: Cardiac & Cardiovascular Systems
`
`View category quartiles
`
`Citation Network
`In WebofScience Core Collection
`
`1Citation
`& Createcitation alert
`
`All Citations
`1 In All Databases
`+ See morecitations
`
`Cited References
`
`0
`
`You mayalsolike...
`Voswinckel, R; van Dijk, J; Rubin,LJ;et al.
`Long Term OpenLabelTreatmentwith Inhaled
`Treprostinil for PulmonaryArterial
`Hypertension
`AMERICAN JOURNALOF RESPIRATORY AND
`CRITICAL CARE MEDICINE
`
`Shapiro, S; Mandras,S; Nelsen, AC; etal.
`Survival and drugpersistencein patients
`receiving inhaledtreprostinil at doses greater
`than 54 mug (nine breaths)four times daily
`PULMONARYCIRCULATION
`
`Khan,AA; Ackerbauer, K; Tandon,R;
`Safety And Tolerability Of Outpatient
`Transition Of Parenteral And Inhaled
`Treprostinil To Oral Treprostinil In Patients
`With PulmonaryArterial Hypertension
`AMERICAN JOURNALOF RESPIRATORY AND
`CRITICAL CARE MEDICINE
`Ford, H; Anderson,W; Carson,S;etal.
`INHALED TREPROSTINIL FOR PATIENTSAT RISK
`FOR ARDS
`CHEST
`Tonelli, AR; Sahay, S; Nelsen,AC;etal.
`Impactofinhaled treprostinil on risk
`stratification with noninvasive parameters: a
`post hocanalysis of the TRIUMPH and BEAT
`studies
`PULMONARYCIRCULATION
`Seeall
`
`MostRecently Cited by
`Ghofrani, HA; Voswinckel, R; Seeger, W;etal.
`Emergingtherapiesfor the treatmentof
`pulmonaryarterial hypertension
`HERZ
`
`Use in WebofScience
`WebofScience Usage Count
`
`1
`Last 180 Days
`Learn more
`
`2
`Since 2013
`
`This record is from:
`Webof Science CoreCollection
`© Conference Proceedings Citation Index -
`Science (CPCI-S)
`© ScienceCitation Index Expanded (SCI-
`EXPANDED)
`
`Suggest a correction
`
`Ifyou wouldlike to improve the quality ofthe
`datain this record, please Suggest a
`correction
`
`Liquidia's Exhibit 1120
`Page 8
`
`Liquidia's Exhibit 1120
`Page 8
`
`